Table 1 Correlation between ZNFTR and clinical characteristics of patient with pancreatic cancer.

From: LncRNA ZNFTR functions as an inhibitor in pancreatic cancer by modulating ATF3/ZNF24/VEGFA pathway

Characteristics

Number of cases

ZNFTR expression

P value

High

Low

Total cases

48

   

Gender

   

0.564

   Male

23

10

13

 

   Female

25

14

11

 

Age

   

0.766

   <60

18

8

10

 

   ≥60

30

16

14

 

Tumor size (cm)

   

0.244

   <2

21

13

8

 

   ≥2

27

11

16

 

Histological grade

   

0.069

   High/moderate

31

12

19

 

   Low

17

12

5

 

TNM stage

   

0.039*

   I–II

20

14

6

 

   III–IV

28

10

18

 

Lymphatic invasion

   

0.019*

   Positive

27

9

18

 

   Negative

21

15

6

 

Vascular invasion

   

0.011*

   Positive

15

3

12

 

   Negative

33

21

12

 

Distant metastasis

   

0.008*

   Positive

22

6

16

 

   Negative

26

18

8

 
  1. The median expression level was used as the cutoff. Low ZNFTR expression in each of the 48 patients was defined as a value below the 50th percentile. High ZNFTR expression in each of the 48 patients was defined as a value above the 50th percentile. Downregulation of ZNFTR was significantly associated with TNM stage, lymphatic invasion, vascular infiltration, and distant metastasis, but not with patients’ gender, age, tumor size, and histological grade (*P < 0.05).
Back to article page